⏳ Fetching live dividend data...
Home › Calculator › SRNEQ Dividend Calculator 2026
Sorrento Therapeutics, Inc. · OTC
Price: $0.03 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SRNEQ → $20125553435718708.00M in 10 years · $1,652,344,288,646,856,200,000.00/month
Sorrento Therapeutics, Inc. is a biopharmaceutical firm that has both clinical-stage and commercial products. It concentrates on developing cutting-edge therapies across three main health domains: oncology, infectious diseases, and pain management. The company is organized into two primary divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library and advanced delivery systems. These include chimeric antigen receptor T-cell (CAR-T) therapy, dimeric CAR-T, antibody drug conjugates, and bispecific antibodies. Additionally, its Sofusa technology allows for direct lymphatic delivery of biologics. Among its active clinical cancer programs are an anti-CD38 CAR-T therapy for multiple myeloma, amyloidosis, and graft-versus-host disease. In the realm of pain relief, the company is advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, to address severe cancer pain and osteoarthritis. Its commercial product, ZTlido, is a lidocaine topical system prescribed for post-herpetic neuralgia. The pipeline also includes SEMDEXA, an injectable viscous gel in Phase III trials for sciatica-related low back pain; SP-103, an investigational non-aqueous lidocaine topical system for chronic low back pain; and SP-104, a novel low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. In infectious disease, Sorrento has partnered with SmartPharm Therapeutics Inc. to create a gene-encoded antibody vaccine targeting COVID-19. Furthermore, it collaborates with the Mayo Clinic on a Phase Ib pilot study, evaluating the Sofusa lymphatic drug delivery system for Ipilimumab in melanoma patients. Established in San Diego, California, in 2006, Sorrento Therapeutics, Inc. recently commenced voluntary reorganization under Chapter 11 bankruptcy. This filing, including an affiliate, occurred on February 13, 2023, within the U.S. Bankruptcy Court for the Southern District of Texas.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SRNEQ position with:
Real after-tax yield depends on where you live and how you hold SRNEQ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 6666.67% | 6663.87% | $666,667 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 5666.67% | 5663.87% | $566,667 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 5333.34% | 5330.54% | $533,334 / yr |
| 🇬🇧 UK ISA | 0% | 6666.67% | 6663.87% | $666,667 / yr |
| 🇬🇧 UK Taxable | 8.75% | 6083.34% | 6080.54% | $608,334 / yr |
| 🇨🇦 TFSA | 0% | 6666.67% | 6663.87% | $666,667 / yr |
| 🇨🇦 CA Taxable | 25% | 5000.00% | 4997.20% | $500,000 / yr |
| 🇦🇺 Super (pension) | 15% | 5666.67% | 5663.87% | $566,667 / yr |
| 🇦🇺 AU Taxable | 30% | 4666.67% | 4663.87% | $466,667 / yr |
| 🇩🇪 DE Taxable | 26.375% | 4908.34% | 4905.54% | $490,834 / yr |
| 🇫🇷 FR Taxable | 30% | 4666.67% | 4663.87% | $466,667 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SRNEQ pays quarterly — 4 times per year. Next ex-div: TBD.
How SRNEQ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SRNEQ sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SRNEQ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Sorrento Therapeutics, Inc. (SRNEQ) is currently trading at $0.03, 98% below its 52-week high. The current dividend yield is 6666.67% based on an annual payout of $2.00 per share.
Sorrento Therapeutics, Inc. (SRNEQ) is a healthcare stock currently trading at $0.03 with a dividend yield of 6666.67%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever